Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRP8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRP8 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View LRP8 Products |
| Gene Delivery | LRP8 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-binding and internalization assays. |
View LRP8 Products |
| Benchmark Ab | Anti-LRP8 Reference Antibody Recombinant positive control derived from published therapeutic research leads. |
View LRP8 Products |
| Validator | LRP8 siRNA Set For knockdown verification and functional specificity validation in vitro. |
View LRP8 Products |
| Related Target A | RELN (Reelin) Primary functional ligand of LRP8. Crucial for ligand-blocking and competitive binding assays. |
View RELN Products |
| Related Target B | VLDLR Co-receptor in the Reelin signaling pathway. Important for selectivity and cross-reactivity profiling. |
View VLDLR Products |
| Related Target C | APOE Key ligand of LRP8 implicated in Alzheimer's disease pathology and lipid metabolism. |
View APOE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Human vs. Mouse/Cyno) | Human, Mouse, and Cynomolgus LRP8 recombinant proteins available with >95% purity verified by SDS-PAGE. |
| Conformational preservation for cell-based screening | Lentiviral vectors with sequence-verified full-length LRP8 for stable, high-expression cell line generation. |
| Lack of reliable positive controls | Clinical-grade benchmark recombinant antibodies included in the catalog for assay calibration. |
| Target specificity confirmation | Sequence-specific siRNA pools for high-efficiency knockdown to eliminate false-positive signals. |
Live LRP8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of LRP8 (Apolipoprotein E Receptor 2 / ApoER2) is gaining traction across oncology, neurology, and autoimmune diseases (such as antiphospholipid syndrome). Traditionally studied in the context of brain development and synaptic plasticity, LRP8 over-expression has recently been identified as a driver of metastasis, drug resistance, and cell survival in triple-negative breast cancer (TNBC), prostate cancer, and endometrial cancer. The race for LRP8 therapeutics is intensifying, with major players shifting focus from traditional functional blocking mAbs to antibody-drug conjugates (ADCs) and bispecific constructs designed to exploit its internalization pathway. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting tumor-specific epitopes and ligand-blocking mechanisms that spare physiological neuronal signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech Startups / Academic Alliances | TNBC, Prostate Cancer, Solid Tumors | Internalization Assay (Requires high-purity, native-glycosylated LRP8 ECD-Fc) |
| Monoclonal Antibodies (mAbs) | Oncology Therapeutics Devs | Metastatic Cancers, Thrombotic Disorders | Ligand-blocking assays (Requires validated recombinant RELN and APOE proteins) |
| Small Molecule Inhibitors | Neurology & Cardiovascular Research Institutes | Alzheimer's Disease, Antiphospholipid Syndrome | Surface binding and signaling assays (Requires LRP8 Stable Cell Lines via Lentivirus) |